ABSTRACT
BACKGROUND: Rapid point-of-care (POC) tests provide an economical alternative for rapid diagnosis and treatment of influenza, especially in public health emergency situations. OBJECTIVES: To test the performance of a rapid influenza diagnostic test, QuickVue (Quidel) as a POC test against a real-time polymerase chain reaction (RT-PCR) assay for detection of influenza A and B in a developing country setting. STUDY DESIGN: In a prospective observational design, 600 patients with influenza-like illness (ILI) or with severe acute respiratory illness (SARI) who were referred to the Influenza Clinic of a tertiary care hospital in Srinagar, India from September 2012 to April 2013, were enrolled for diagnostic testing for influenza using QuickVue or RT-PCR. All influenza A-positive patients by RT-PCR were further subtyped using primers and probes for A/H1pdm09 and A/H3. RESULTS: Of the 600 patients, 186 tested positive for influenza A or B by RT-PCR (90 A/H1N1pdm09, 7 A/H3 and 89 influenza B), whereas only 43 tested positive for influenza (influenza A=22 and influenza B=21) by QuickVue. Thus, the sensitivity of the QuickVue was only 23% (95% confidence interval, CI: 17.3-29.8) and specificity was 100% (95% CI: 99.1-100) with a positive predictive value (PPV) of 100% (95% CI 91.8-100) and a negative predictive value (NPV) of 74.3% (95% CI: 70.5-77.9) as compared to RT-PCR. CONCLUSIONS: The high specificity of QuickVue suggest that this POC test can be a useful tool for patient management or triaging during a public health crisis but a low sensitivity suggests that a negative test result need to be further tested using RT-PCR.
Subject(s)
Influenza A virus/genetics , Influenza B virus/genetics , Influenza, Human/diagnosis , Point-of-Care Systems , Real-Time Polymerase Chain Reaction , Adult , Female , Humans , India , Male , Point-of-Care Systems/economics , Real-Time Polymerase Chain Reaction/methods , Reproducibility of Results , Sensitivity and Specificity , Young AdultABSTRACT
Apoptosis induction is an antiviral host response, however, influenza A virus (IAV) infection promotes host cell death. The nucleoprotein (NP) of IAV is known to contribute to viral pathogenesis, but its role in virus-induced host cell death was hitherto unknown. We observed that NP contributes to IAV infection induced cell death and heterologous expression of NP alone can induce apoptosis in human airway epithelial cells. The apoptotic effect of IAV NP was significant when compared with other known proapoptotic proteins of IAV. The cell death induced by IAV NP was executed through the intrinsic apoptosis pathway. We screened host cellular factors for those that may be targeted by NP for inducing apoptosis and identified human antiapoptotic protein Clusterin (CLU) as a novel interacting partner. The interaction between IAV NP and CLU was highly conserved and mediated through ß-chain of the CLU protein. Also CLU was found to interact specifically with IAV NP and not with any other known apoptosis modulatory protein of IAV. CLU prevents induction of the intrinsic apoptosis pathway by binding to Bax and inhibiting its movement into the mitochondria. We found that the expression of IAV NP reduced the association between CLU and Bax in mammalian cells. Further, we observed that CLU overexpression attenuated NP-induced cell death and had a negative effect on IAV replication. Collectively, these findings indicate a new function for IAV NP in inducing host cell death and suggest a role for the host antiapoptotic protein CLU in this process.
Subject(s)
Clusterin/metabolism , Epithelial Cells/metabolism , Influenza A virus/metabolism , RNA-Binding Proteins/metabolism , Respiratory Mucosa/metabolism , Viral Core Proteins/metabolism , Apoptosis , Binding Sites , Cell Line , Clusterin/genetics , Epithelial Cells/pathology , Epithelial Cells/virology , Gene Expression Regulation , Host-Pathogen Interactions , Humans , Influenza A virus/genetics , Mitochondria , Nucleocapsid Proteins , Protein Binding , Protein Transport , RNA, Small Interfering/genetics , RNA-Binding Proteins/antagonists & inhibitors , RNA-Binding Proteins/genetics , Respiratory Mucosa/pathology , Respiratory Mucosa/virology , Signal Transduction , Viral Core Proteins/antagonists & inhibitors , Viral Core Proteins/genetics , bcl-2-Associated X ProteinABSTRACT
Mycobacterium xenopi can cause opportunistic infections, particularly in persons infected with human immunodeficiency virus type 1 (HIV-1). The primary focus of this effort was to determine if M. xenopi isolates could survive and grow in human peripheral blood macrophage (MPhi), and if these isolates could promote the replication of HIV-1 in vitro. M. xenopi bacilli survived and replicated 10-fold within 48 h in human MPhi while avirulent Mycobacterium smegmatis, did not grow within the MPhi. M. xenopi bacilli when cultured with peripheral blood mononuclear cells enhanced HIV-1 replication 30- and 50-fold with the macrophage-tropic HIV-1(Ba-L) and 50- and 75-fold with T-cell-tropic strain HIV-1(LAI) by 6 days post-infection when compared to M. smegmatis. The enhanced HIV replication was associated with increased production of TNF-alpha. Partial inhibition of HIV-1 induction was observed using a neutralizing anti-TNF-alpha monoclonal antibody, pentoxifylline, and matrix metalloproteinase (MMP) inhibitor I. Similar mechanisms of pathogenesis among mycobacterial species may help elucidate better treatment approaches in HIV co-infected persons.
Subject(s)
HIV Infections/complications , HIV-1/physiology , Macrophages/microbiology , Mycobacterium Infections, Nontuberculous/complications , Mycobacterium xenopi/growth & development , Virus Replication/physiology , AIDS-Related Opportunistic Infections/microbiology , Amikacin/pharmacology , Anti-Bacterial Agents/pharmacology , Cells, Cultured , Enzyme-Linked Immunosorbent Assay/methods , Gene Products, gag/analysis , Humans , Matrix Metalloproteinase 2/metabolism , Matrix Metalloproteinase 9/metabolism , Matrix Metalloproteinase Inhibitors , Mycobacterium Infections, Nontuberculous/blood , Mycobacterium Infections, Nontuberculous/microbiology , Mycobacterium xenopi/pathogenicity , Mycobacterium xenopi/physiology , Time Factors , Tissue Inhibitor of Metalloproteinase-1/metabolism , Tumor Necrosis Factor-alpha/immunology , Tumor Necrosis Factor-alpha/metabolism , Virus Activation/physiology , gag Gene Products, Human Immunodeficiency VirusABSTRACT
The ability of certain theta-defensins, including retrocyclin-1, to protect human cells from infection by HIV-1 marks them as potentially useful molecules. Theta-defensins composed of L-amino acids are likely to be unstable in environments that contain host and microbial proteases. This study compared the properties of two enantiomeric theta-defensins, retrocyclin-1, and RC-112. Although these peptides have identical sequences, RC-112 is composed exclusively of D-amino acids, whereas retrocyclin-1 contains only L-amino acids. We compared the ability of these peptides to protect JC53-BL human cells from infection by 30 primary HIV-1 isolates. JC53-BL cells are modified HeLa cells that express surface CD4, CXCR4, and CCR5. They also contain reporter cassettes that are driven by the HIV-1 LTR, and express beta-galactosidase and luciferase. The HIV-1 isolates varied in co-receptor specificity and included subtypes A, B, C, D, CRF01-AE, and G. RC-112 was several fold more potent than retrocyclin-1 across the entire HIV-1 panel. Although RC-112 bound immobilized gp120 and CD4 with lower affinity than did retrocyclin-1, surface plasmon resonance experiments performed with 1 microg/mL of RC-112 and retrocyclin-1 revealed that both glycoproteins were bound to a similar extent. The superior antiviral performance of RC-112 most likely reflected its resistance to degradation by surface-associated or secreted proteases of the JC53-BL target cells. Theta-defensins composed exclusively of D-amino acids merit consideration as starting points for designing microbicides for topical application to the vagina or rectum.
Subject(s)
Defensins/chemistry , Defensins/pharmacology , HIV-1/drug effects , Amino Acids/chemistry , Animals , Anti-HIV Agents/pharmacology , Defensins/metabolism , HIV Infections/drug therapy , Humans , StereoisomerismABSTRACT
Since expression of both interleukin-2 (IL-2) and IL-2-receptor-alpha (IL-2R-alpha) by lymphocytes is inhibited by human immunodeficiency virus (HIV) in vitro, we hypothesized that HIV-co-infection among persons with tuberculosis (TB) might impair T-lymphocyte responses to TB via this mechanism. We measured soluble IL-2R-alpha (sIL-2R-alpha), a surrogate marker of T-lymphocyte activation and proliferation, and soluble tumour necrosis factor receptor I (sTNF-RI) in sera from West African patients categorized into 4 groups: those with TB alone (TB+ HIV-, n = 55), CD4-matched groups with TB and HIV co-infection (TB+ HIV+, n = 50) or HIV infection alone (TB- HIV+, n = 35), and patients with neither disease (TB- HIV-, n = 35). The median level of sIL-2R-alpha was markedly greater in the TB+ HIV- group (1580 U/mL) compared to the TB- HIV- (670 U/mL; P < 0.001) and TB- HIV+ (880 U/mL; P < 0.01) groups. More importantly, the median concentration of sIL-2R-alpha was much lower in the TB+ HIV+ group (855 U/mL) compared to the TB+ HIV- group (1580 U/mL; P < 0.01) despite similar levels of sTNF-RI. These results suggest that T-lymphocyte activation in TB patients is impaired by HIV co-infection and, furthermore, this suppressive effect was independent of numerical depletion of CD4 lymphocytes. Impairment to IL-2-signalling might contribute to the profound impact that HIV has had on both the incidence and the clinicopathological manifestations of TB.
Subject(s)
AIDS-Related Opportunistic Infections/complications , Receptors, Interleukin-2/metabolism , T-Lymphocytes/immunology , Tuberculosis/complications , AIDS-Related Opportunistic Infections/immunology , Adult , Animals , Cross-Sectional Studies , Female , Humans , Male , Mycobacterium tuberculosis/immunology , Mycobacterium tuberculosis/pathogenicity , Tuberculosis/immunologyABSTRACT
Phenotypic change and broader coreceptor usage by HIV-1 have been associated with disease progression. HIV-1 coreceptor usage by primary isolates obtained from HIV-1-infected and HIV-1/HTLV-II-coinfected individuals was determined. HIV-1 was isolated from 15 of 20 HIV-1-infected and 17 of 24 HIV-1/HTLV-II-coinfected individuals. None of the isolates from either the HIV-1-infected or the coinfected group infected CCR5delta32 PBMCs, suggesting that they all were R5-tropic. Further, both spontaneous and PHA-stimulated production of MIP-1beta and RANTES were similar in HIV-1-infected and coinfected individuals. These data indicate that coinfection with HTLV-II has no effect on HIV-1 coreceptor usage or ex vivo beta-chemokine production.
Subject(s)
HIV Infections/complications , HIV-1/physiology , HTLV-II Infections/complications , Human T-lymphotropic virus 2/physiology , CD4-Positive T-Lymphocytes/virology , Chemokines, CC/metabolism , Disease Progression , HIV Infections/immunology , HIV Infections/virology , HIV-1/classification , HTLV-II Infections/immunology , HTLV-II Infections/virology , Humans , Phenotype , Receptors, CCR5/metabolismABSTRACT
Understanding how highly HIV-exposed individuals remain HIV uninfected may be useful for HIV vaccine design and development of new HIV prevention strategies. To elucidate mechanisms associated with resistance to HIV infection, immunologic and genetic factors were examined in 14 HIV-exposed but persistently seronegative (HEPS) female sex workers from Chiang Rai, northern Thailand and in ethnically matched, HIV-positive (n = 9) and HIV-negative women (n = 9). The HEPS women were identified in a study of commercial sex workers who had an HIV-1 incidence of 20.3 per 100 person-years. A high frequency of HLA-A11 was observed in HEPS women (86%) compared with northern Thai controls (56%). HIV-specific cytotoxic T lymphocyte (CTL) lytic responses were detected in cryopreserved peripheral blood mononuclear cells (PBMCs), using HLA-A-matched subtype E HIV-1 peptides in four of seven (57%) HEPS women, eight of eight HIV-positive women, and zero of nine HIV-negative unexposed controls (p = 0.019 HEPS women vs. HIV-negative controls). CTL lysis levels were low, but responses were detected to peptides from Nef, Pol, Gag, and Env. Nef responses predominated in HEPS women. Compared with controls, HEPS women tended to have higher frequencies of CCR5 promotor 59402GG and SDF-1 3'UTR 801A genotypes known to influence HIV transmission or course of disease. HEPS women also had higher levels of spontaneous RANTES production by PBMCs than other groups. Each of these factors could potentially contribute to HIV resistance. As most HEPS women had one or more of these factors, they may prevent HIV infection synergistically by blocking HIV cell entry, delaying its dissemination, or killing HIV-infected cells.
Subject(s)
HIV Infections/immunology , HIV Seronegativity/immunology , HIV-1/immunology , HLA-A Antigens/immunology , Receptors, CCR5/metabolism , T-Lymphocytes, Cytotoxic/immunology , Adult , Alleles , Cells, Cultured , Chemokine CCL5/analysis , Cohort Studies , Cytotoxicity Tests, Immunologic , Female , Gene Products, env/immunology , Gene Products, gag/immunology , Gene Products, nef/immunology , Gene Products, pol/immunology , HLA-A11 Antigen , Humans , Leukocytes, Mononuclear/immunology , Middle Aged , Sex Work , Thailand , Viral Proteins/immunology , nef Gene Products, Human Immunodeficiency VirusABSTRACT
Six Food and Drug Administration (FDA)-licensed human immunodeficiency virus type 1 (HIV-1) and HIV-1/2 immunoassays, including five enzyme immunoassays and one rapid test, were challenged with up to 250 serum samples collected from various global sites. The serum samples were from individuals known to be infected with variants of HIV-1 including group M subtypes A, B, B', C, D, E, F, and G and group O. All immunoassays detected the vast majority of samples tested. Three samples produced low signal over cutoff values in one or more tests: a clade B sample, an untypeable sample with a low antibody titer, and a group O sample. It is concluded that HIV-1 immunoassays used in the United States are capable of detecting most HIV-1 group M variants.
Subject(s)
AIDS Serodiagnosis/methods , HIV Antibodies/blood , HIV-1/classification , HIV-1/immunology , Immunoassay/methods , Amino Acid Sequence , HIV Antigens/chemistry , HIV Antigens/immunology , HIV Infections/diagnosis , HIV Infections/virology , HIV-1/genetics , HIV-1/isolation & purification , Humans , Molecular Sequence Data , Reagent Kits, Diagnostic , Sensitivity and Specificity , Sequence Analysis, DNA , United States , United States Food and Drug AdministrationABSTRACT
Primary prostate and cervical epithelial cells and epithelial cell lines were examined for human immunodeficiency virus type 1 (HIV-1) infection or transmission to peripheral blood mononuclear cells (PBMC). Neither cell-free nor cell-associated HIV-1 infected primary epithelial cells or cell lines. Pretreatment of HIV-1 to enhance CD4-independent entry did not augment infection. Cell surface expression was detected for galactosyl ceramide but not for CC-chemokine receptor 5, CXC-chemokine receptor 4, or CD4. The ability to transfer HIV-1 to resting or activated PBMC was tested by culturing with rinsed or trypsinized and replated HIV-1-exposed epithelial cells. Virus was not recovered from the rinsed or replated cocultures with resting PBMC; however, activated PBMC recovered HIV-1 from rinsed epithelial cells and rarely from replated epithelial cells. Although urogenital epithelial cells are not infected, these data suggest that they can transfer virus to activated immune cells and have implications for sexual transmission of HIV-1.
Subject(s)
Cervix Uteri/virology , Epithelial Cells/virology , HIV-1/physiology , Lymphocytes/virology , Prostate/virology , CD4 Antigens/analysis , CD4-Positive T-Lymphocytes/virology , Cathepsin D/pharmacology , Cell Line , Cells, Cultured , Cervix Uteri/immunology , Epithelial Cells/immunology , Female , Galactosylceramides/analysis , HIV-1/isolation & purification , HLA-DR Antigens/analysis , Humans , Intestinal Mucosa/virology , Lymphocyte Activation , Lymphocytes/immunology , Male , Prostate/immunology , Receptors, CCR5/analysis , Receptors, CXCR4/analysisABSTRACT
We have investigated the genetic diversity and potential mosaic genomes of HIV-1 during the early part of the HIV-1 epidemic among commercial sex workers (CSWs) in Kinshasa, Democratic Republic of Congo (formerly Zaire). Serologic analysis revealed that 27 (28.7%) of the 94 specimens were seropositive by both peptide and whole-virus lysate EIAs and that 24 were positive by molecular screening assays, using generic primers that can detect all known groups of HIV-1. Phylogenetic analyses of the gag(p24), C2V3, and gp41 regions of these 24 specimens showed that all were group M; none of them had any evidence of group O, N, or SIVcpz-like sequences. On the basis of env sequence analysis, the 24 group M specimens were classified as subtypes G (37.5%), A (21%), F1 (12.5%), CRF01_AE (8%), D (4%), and H (4%); 3 (12.5%) were unclassifiable (U). Similar analysis of the gag(p24) region revealed that the majority of infections were subtype A; however, one-third of the specimens were subtype G. Parallel analysis of gag(p24) and env regions revealed discordant subtypes in many specimens that may reflect possible dual and/or recombinant viruses. These data suggest a predominance of subtype G (both pure G and recombinant CRF02_AG) during the early part of the epidemic in Kinshasa. Infections with group N or SIVcpz-like viruses were not present among these CSWs in Kinshasa.
Subject(s)
HIV Infections/epidemiology , HIV-1/classification , HIV-1/genetics , Sex Work , Democratic Republic of the Congo/epidemiology , Female , Genetic Variation , HIV , HIV Core Protein p24/genetics , HIV Envelope Protein gp120/genetics , HIV Envelope Protein gp41/genetics , HIV Infections/virology , Humans , Molecular Sequence Data , Peptide Fragments/genetics , Phylogeny , RNA, Viral/blood , Sequence Analysis, DNASubject(s)
HIV Infections/etiology , HIV-1 , Acquired Immunodeficiency Syndrome/epidemiology , Acquired Immunodeficiency Syndrome/etiology , Acquired Immunodeficiency Syndrome/immunology , Africa/epidemiology , Comorbidity , Disease Progression , Disease Susceptibility/immunology , HIV Infections/epidemiology , HIV Infections/immunology , Helminthiasis/epidemiology , Helminthiasis/etiology , Humans , Incidence , Prevalence , Protozoan Infections/etiology , Sexually Transmitted Diseases/etiology , Tuberculosis/epidemiology , Tuberculosis/etiologyABSTRACT
The aim of this study was to identify immune markers that are independently associated with HIV infection or TB in vivo. Using commercially available assays, we measured concentrations of five immune markers in sera from 175 out-patients attending medical clinics in Cote D'Ivoire and Ghana, West Africa. Patients were categorized into groups with TB only (TB+HIV-, n = 55), TB and HIV co-infection (TB+HIV+, n = 50), HIV infection only (TB-HIV+, n = 35), or neither infection (TB-HIV-, n = 35). TB+HIV+ and TB-HIV+ groups were matched for blood CD4+ lymphocyte count. Mean +/- s.d. concentrations of beta2-microglobulin were similarly increased in both the TB-HIV+ (5.3+/-2.1 microg/ml, P<0.0001) and the TB+HIV+ (5.0+/-1.5 microg/ml, P<0.0001) groups compared with the TB-HIV- group (2.2+/-1.8 microg/ml), but were only slightly increased in the TB+HIV- group (3.2+/-1.8 microg/ml, P = 0.01). In contrast, mean serum concentrations of soluble tumour necrosis factor receptor type I (sTNF-RI) were similarly elevated in the TB+HIV- (1873+/-799 pg/ml, P<0.0001) and TB+HIV+ (1797+/-571 pg/ml, P<0.0001) groups compared with uninfected subjects (906+/-613 pg/ml), but there was only a small increase in sTNF-RI in the TB-HIV+ group (1231+/-165 pg/ml, P = 0.03). Both TB and HIV infection were associated with substantial elevation of serum concentrations of soluble CD8, soluble CD54, and sTNF-R type II. Analysis of additional samples from groups of TB+HIV- and TB+HIV+ patients receiving anti-TB treatment showed significant and equal reductions in mean serum sTNF-RI concentrations, but no significant change in mean beta2-microglobulin. Thus, serum beta2-microglobulin and sTNF-RI serve as relatively independent markers of HIV infection and TB, respectively, in studies of co-infected persons.
Subject(s)
Antigens, CD/blood , HIV Infections/immunology , Receptors, Tumor Necrosis Factor/blood , Tuberculosis/immunology , beta 2-Microglobulin/blood , Adult , Antitubercular Agents/therapeutic use , Biomarkers , Cross-Sectional Studies , Female , HIV Infections/blood , Humans , Male , Receptors, Tumor Necrosis Factor, Type I , Tuberculosis/blood , Tuberculosis/drug therapyABSTRACT
Phylogenetic analysis of the gp41 region of 123 HIV-1-seropositive specimens from Cameroon showed that 89 were subtype A (71% of these sequences were IbNg-like), 12 (10%) were subtype D, 11 (9%) were subtype G, 5 (4%; closely related to subtype F2) were subtype F, 1 was subtype H, 2 (1.6%) remained unclassifiable, while 3 were group O. Further analysis of the two unclassifiable specimens in gag(p24), pol(prot), and env (C2V3 or gp41) showed that one (98CM19) was a complex mosaic between subtype A in p24 and subtype J prot, and unclassifiable in env (C2V3 or gp41). The second, 98CM63, clustered distinctly from all known subtypes in p24, prot, C2V3, or gp41. 98CM63 clustered with a specimen from Cyprus and these two geographically and epidemiologically unlinked specimens, with their distinct clustering pattern, may represent a new subcluster of subtype A. In conclusion, these findings confirm the high HIV-1 genetic variability and further suggest the continuous appearance of new viral strains in this population.
Subject(s)
Genetic Variation/genetics , HIV Envelope Protein gp41/genetics , HIV Infections/virology , HIV-1/genetics , Amino Acid Sequence , Cameroon/epidemiology , Gene Products, pol/genetics , HIV Core Protein p24/genetics , HIV Envelope Protein gp120 , HIV Infections/epidemiology , HIV-1/classification , Humans , Molecular Sequence Data , Peptide Fragments , Phylogeny , Sequence Analysis, DNAABSTRACT
The molecular diversity and phylogenetic relationship of 22 HIV-1 group O strains were examined on the basis of the protease gene and the N-terminal region of gp41env. Analysis of the newly characterized protease sequences with 12 reference sequences revealed no specific clustering patterns, despite the distinct geographic locations of the specimens. In contrast, analysis of the newly sequenced gp41 sequences with 34 published sequences revealed two distinct clusters, each represented by one full-length sequence (MVP5180 and ANT-70). Further, four of the specimens classified as group O in the protease region clustered with group M in the gp41 region (three subtype A and one subtype G, respectively), suggesting dual and/or recombinant infections with HIV-1 groups M and O. The presence of two distinct clusters in the gp41 region indicates at least two possible subtypes within group O viruses, and this may provide useful information regarding molecular epidemiological studies of group O infections.
Subject(s)
HIV Envelope Protein gp41/genetics , HIV Infections/epidemiology , HIV Protease/genetics , HIV-1/genetics , Phylogeny , Amino Acid Sequence , Genes, Viral , Genes, env , HIV Envelope Protein gp41/chemistry , HIV Infections/virology , HIV-1/classification , Humans , Molecular Sequence Data , Sequence Analysis, DNAABSTRACT
An intravenous drug user was found to be dually infected with two genetically and phylogenetically distinct human immunodeficiency virus type 1 (HIV-1) subtype B strains (designated groups I and II). Viral isolation revealed a simultaneous copassaging of two strains in PBMC. The culture of viral strains on monocytes and monocyte-derived macrophages preferentially segregated the two viral strains. The group I strain utilized CXCR4 and group II used CCR5 coreceptor for entry. Sequencing of >100 clones from uncultured PBMC consistently showed the predominance of group II virus in vivo. Importantly, the group II virus alone could not productively infect PBMC, but when used together with group I virus for infection, the group II virus regained its high replication potential and predominance in cultured PBMC. These data are the first to provide direct evidence in favor of molecular and biological interaction between two infecting strains in a coinfected patient and show their differential pathogenic effects, tropism, and modes of entry. In addition, our data provide the first evidence for synergism between these two strains. Cumulatively, these data emphasize that in order to clearly interpret coreceptor usage, biological segregation of viral strains from primary isolates in vitro may be imperative.
Subject(s)
HIV Infections/virology , HIV-1/physiology , Amino Acid Sequence , Cloning, Molecular , Female , Gene Products, vpr/genetics , HIV Envelope Protein gp120/genetics , HIV Infections/complications , HIV-1/classification , HIV-1/genetics , Humans , Microscopy, Electron/methods , Molecular Sequence Data , Peptide Fragments/genetics , Phenotype , Phylogeny , Polymerase Chain Reaction/methods , Receptors, CCR5/metabolism , Receptors, CXCR4/metabolism , Recombination, Genetic , vpr Gene Products, Human Immunodeficiency VirusABSTRACT
We have used coreceptor-targeted inhibitors to investigate which coreceptors are used by human immunodeficiency virus type 1 (HIV-1), simian immunodeficiency viruses (SIV), and human immunodeficiency virus type 2 (HIV-2) to enter peripheral blood mononuclear cells (PBMC). The inhibitors are TAK-779, which is specific for CCR5 and CCR2, aminooxypentane-RANTES, which blocks entry via CCR5 and CCR3, and AMD3100, which targets CXCR4. We found that for all the HIV-1 isolates and all but one of the HIV-2 isolates tested, the only relevant coreceptors were CCR5 and CXCR4. However, one HIV-2 isolate replicated in human PBMC even in the presence of TAK-779 and AMD3100, suggesting that it might use an undefined, alternative coreceptor that is expressed in the cells of some individuals. SIV(mac)239 and SIV(mac)251 (from macaques) were also able to use an alternative coreceptor to enter PBMC from some, but not all, human and macaque donors. The replication in human PBMC of SIV(rcm) (from a red-capped mangabey), a virus which uses CCR2 but not CCR5 for entry, was blocked by TAK-779, suggesting that CCR2 is indeed the paramount coreceptor for this virus in primary cells.
Subject(s)
Anti-HIV Agents/pharmacology , HIV-1/physiology , HIV-2/physiology , Receptors, HIV/metabolism , Receptors, Virus/metabolism , Simian Immunodeficiency Virus/physiology , Amides/pharmacology , Animals , Benzylamines , CD4 Antigens/metabolism , Cell Line , Chemokine CCL5/analogs & derivatives , Chemokine CCL5/pharmacology , Cyclams , HIV-1/drug effects , HIV-1/pathogenicity , HIV-2/drug effects , HIV-2/pathogenicity , Heterocyclic Compounds/pharmacology , Humans , Leukocytes, Mononuclear/virology , Lymphocytes , Macaca , Quaternary Ammonium Compounds/pharmacology , Receptors, CCR2 , Receptors, CCR3 , Receptors, CCR5/metabolism , Receptors, Chemokine/metabolism , Receptors, HIV/antagonists & inhibitors , Receptors, Virus/antagonists & inhibitors , Simian Immunodeficiency Virus/drug effects , Simian Immunodeficiency Virus/pathogenicity , Transfection , Tumor Cells, Cultured , Virus Replication/drug effectsABSTRACT
Cross-species transmission has been shown to play an important role in the emergence of human retroviruses. We developed a generic enzyme immunoassay using synthetic peptides from gp41 and C2V3 consensus sequences (human immunodeficiency virus [HIV] type 1 [HIV-1] groups M, O, and N and the homologous region of simian immunodeficiency virus [SIV] strains from chimpanzees [SIVcpz], SIVcpzGAB1 and SIVcpzANT) to detect divergent HIV and SIV. A cocktail of peptides from gp41 and C2V3 (M-O) detected all HIV-1 group M and O sera and showed cross-reactivity with SIVcpz sera. Further, a mixture of C2V3 peptides (GAB1-ANT) failed to detect HIV-1 infections but reacted with all SIVcpz sera, allowing discrimination of SIVcpz from HIV-1 infections. Since most SIVcpz sera cross-reacted with HIV-1 peptides, we next evaluated SIVcpz serum reactivity with rapid tests for HIV-1/2. SIVcpzANT and SIVcpzUS sera reacted with the Sero-strip and Multispot assays. Both tests are sensitive in detecting group M (97 100%, respectively), although Multispot has lower sensitivity for group O detection (67%) than does Sero-strip (100%). The limited volume and time required to perform these assays make them a generic tool for field screening. The env peptide-based assay and rapid tests should allow for the identification of emerging variants of HIV and SIV.